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Coronary Artery Calcium Progression:
An Important Clinical Measurement?
A Review of Published Reports
John W. McEvoy, MB,* Michael J. Blaha, MD, MPH,* Andrew P. DeFilippis, MD, MSC,*
Matthew J. Budoff, MD,† Khurram Nasir, MD, MPH,*‡ Roger S. Blumenthal, MD,*
Steven R. Jones, MD*
Baltimore, Maryland; Torrance, California; and New Haven, Connecticut
Baseline coronary artery calcification (CAC) accurately identifies coronary atherosclerosis and might improve predic-
tion of future cardiac events. Serial assessment of CAC scores has been proposed for monitoring atherosclerosis pro-
gression and for assessing the effectiveness of medical therapies aimed at reducing cardiac risk. However, whether
knowledge of progression of CAC scores over time further improves risk prediction is unclear. Several trials relating
medical therapies to CAC progression have been performed without any formal guidelines on the definition of CAC
progression and how it is best quantified. We conducted a comprehensive review of published reports on CAC pro-
gression. Increased CAC progression is associated with many known cardiac risk factors. We found that CAC progres-
sion correlates with worsening atherosclerosis and may facilitate prediction of future cardiac events. These findings
support the notion that slowing CAC progression with therapeutic interventions might provide prognostic benefit. How-
ever, despite promising early data, such interventions (most notably with statin therapy) have not been shown to slow
the progression of CAC in any randomized controlled trial to date, outside of post hoc subgroup analyses. Thus, rou-
tine quantification of CAC progression cannot currently be recommended in clinical practice. First, standards of how
CAC progression should be defined and assessed need to be developed. In addition, there remains a need for further
studies analyzing the effect of other cardiac therapies on CAC progression and cardiac outcomes. (J Am Coll Cardiol
2010;56:1613–22) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.038t
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Itherosclerosis is a dynamic process, as demonstrated by
tudies documenting both plaque progression and regression
1). Coronary artery calcification (CAC) is characteristic of
therosclerosis (2) and should also be considered a dynamic
rocess subject to influence by environmental factors and
herapeutic interventions.
Baseline measures of CAC, as quantified by cardiac
omputed tomography (CT), have been shown to predict
uture cardiovascular events in multiple populations (3).
his has led to a Class IIb recommendation by the Amer-
can Heart Association (AHA) for the use of CAC quan-
ification in intermediate risk patients to improve risk
ssessment (4). However, no formal recommendations exist
egarding the clinical use of CAC progression.
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010, accepted June 15, 2010.CAC progression has the potential to better capture
emporal exposure to risk factors as compared with a
aseline CAC score. For example, baseline CAC can be
hought of as a single point on an atherosclerosis versus time
urve, whereas progression correlates with the slope of that
urve. Thus, CAC progression may also be more predictive
f future coronary heart disease events than any current
raditional risk factors, all of which are static clinical
arameters. Similarly, although baseline CAC might reflect
rior coronary atherosclerotic plaque burden, CAC progres-
ion might provide insight into ongoing current disease
ctivity.
In this report, we focus on CAC progression rather than
aseline assessment of CAC. We review the pathophysio-
ogic understanding of CAC progression, the influence of
linical parameters on CAC progression, and treatment
trategies aimed at slowing this progression. Recommenda-
ions for quantifying CAC progression and identifying areas
n need of future research are also discussed.
athophysiology of CAC Progression
n brief, the presence of subintimal coronary calcification is
haracteristic of atherosclerosis (Fig. 1) (5). The AHA
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Coronary Artery Calcification Progression Review November 9, 2010:1613–22endorses a usual pattern of ath-
erosclerosis progression in which
coronary calcification appears in
type 5 lesions (fibroatheroma)
downstream from type IV lesions
(formed atheroma). This occurs
as a consequence of type-4 lesion
instability and rupture, with sub-
sequent calcification as part of
the healing process (Fig. 1) (6).
This process has some resem-
blance to bone formation (7,8).
The formation of calcification in
healing plaques has led to specu-
lation that local CAC progres-
sion might correlate with pro-
gression of noncalcified plaque to
more pathologically stable calci-
fied plaque. For instance, acute
coronary syndromes are associ-
ated with a relative lack of cal-
cium in the culprit stenoses com-
ared with stenoses of patients with stable angina (9).
owever, despite the potential local stability of CAC
laque, experimental studies suggest that intimal calcifica-
ion might itself induce further inflammation and calcifica-
ion in a positive feedback loop, driving CAC progression
urther in patients with positive baseline CAC (10).
easuring CAC Progression
wo modes of cardiac CT can be employed for CAC quan-
ification, electron beam computed tomography (EBCT) and
ultidetector computed tomography (MDCT). Electron
eam computed tomography allows faster imaging by moving
he X-ray source-point electronically rather than mechanically.
dvantages of MDCT are its higher spatial resolution and
heaper cost. To achieve level 2 certification in cardiac CT, one
ust complete at least 2 months of training and have per-
ormed a minimum of 50 cases and interpreted a minimum of
50 cases (11).
CAC is defined as a hyper-attenuating lesion 130
ounsfield units with an area of 3 pixels. Baseline CAC
as been quantified by several methods. The Agatston unit
AU) score is calculated by multiplying the lesion area
mm2) by a density factor (between 1 and 4) (12). Because
f the stepwise nature of the density factor, changes in the
gatston score might not accurately capture changes in
oronary calcium. In contrast to the AU, the calcium
olume score (CVS) represents an actual volume of CAC
nd reduces variability between scans (13) (as does the CAC
ass score [14]). The CVS might also have more biological
lausibility, because an increase in Agatston score might
epresent an increase in plaque attenuation over time, not an
Abbreviations
and Acronyms
AHA  American Heart
Association
AU  Agatston unit
CAC  coronary artery
calcification
CRP  C-reactive protein
CT  computed
tomography
CVS  calcium volume
score
EBCT  electron beam
computed tomography
LDL-C  low-density
lipoprotein cholesterol
MDCT  multidetector
computed tomography
RCT  randomized
controlled trialncrease in plaque size. iProgression can be quantified as absolute change in either
U or CVS score or as percentage relative change. How-
ver, there is no current standardization of how progression
hould be assessed and exactly what meaningful “progres-
ion” constitutes. For example, interscan variability means
hat simply classifying progression as any increase in CAC
core might be inaccurate.
An original pilot study documented a “usual” CAC
rogression rate of 24% increase each year (15). This was a
ollow-up study of 88 patients (55% male) with a mean age
f 46 years, a mean systolic blood pressure of 118 mm Hg,
nd mean total cholesterol of 197 mg/dl. Annual rates
anging from 20% to 30% have since been reported in
atients at average Framingham risk in other studies
16,17).
AC progression: methodology and variability. Mea-
urement of CAC progression depends on accurate repro-
ucibility of CAC scores (Table 1) (13,14,18–21). In gen-
ral, interscan variability increases as levels of baseline CAC
ncrease and can introduce a bias in the evaluation of CAC
rogression (18). Thus, measuring progression by change in
bsolute CAC can introduce an overestimation of the actual
rogression of atherosclerosis in subjects with high baseline
AC as compared with those with low baseline CAC.
sing the percentage change in CAC has the opposite
ffect—overestimating the true progression of atherosclero-
is in those with low baseline CAC. To illustrate, a score of
progressing to 9 is a relative increase of 50%, which is the
ame as for a score of 100 progressing to 150.
Reducing variability between scans is paramount to ac-
urately quantify progression. Improved image acquisition
nd electrocardiographic gating (21) with EBCT has re-
uced the mean interscan variability to between 16% and
9% (22).
Mathematical transformations of the CVS have been
ttempted to further reduce variability. The logistic trans-
ormation has been used with some success (23). Hokanson
t al. (18) found that the square root transformation of CVS
rovides a stable estimate of interscan variability across the
ange of baseline CAC. They suggested using a progression
f square root–transformed CVS of 2.5 mm3 to signify a
ignificant change in CVS. A change of this magnitude is
1% likely to be due to interscan variability. Square root
ransformation can also be applied to AU but has not been
tudied in this regard.
Budoff et al. (24) found that the Hokanson method of
AC progression was the most accurate predictor of mor-
ality (p  0.0001) in 4,609 patients followed for a mean of
years after controlling for baseline CAC, age, sex, and
ollow-up time between scans.
Most of the aforementioned studies were performed with
BCT imaging, because MDCT initially suffered from
ncreased variability due to reduced temporal resolution and
etrospective gating (25). However, recent improvements in
maging protocols have decreased MDCT variability signif-
cantly, such that it now equates with EBCT (26).
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November 9, 2010:1613–22 Coronary Artery Calcification Progression ReviewThus, interscan variability by either modality is now
elow the expected annual rate of CAC progression (20%)
15–17).
ther limitations of CAC progression application. Ad-
ances in CAC quantification methodology over time have
ampered the comparison of datasets. This is due to varying
ethods of image acquisition (EBCT vs. MDCT) (23,27),
arying cutoffs for a positive score (2 to 4 pixels of 130
ounsfield units), varying score reports (Agatston vs. CVS)
23), and different timing of image acquisition within the
ardiac cycle (80% of RR interval vs. 40%) (28). The use of
Figure 1 Pathophysiology of CAC Progression
Increasing coronary artery calcification (CAC) increases risk for future events. CAC
3) CAC progressors. See the text for further details. The correlation of plaque type
part of any formal classification. Once calcification predominates in type 6 lesions
ariability of CAC: Baseline and ProgressionTable 1 Variability of CAC: Baseline and Progression
Baseline CAC
Measure Variability Measure
AU Reference measure Absolute change
CVS 32% reduced vs. AU (13,14)
9% reduced vs. AU (23)
Percentage change
CAC mass 54% reduced vs. AU (14) Log transformation
Square root transforma
(Hokanson)
Regression methodU  Agatston units; CAC  coronary artery calcification; CVS  calcium volume score.ifferent measures of “progression” (absolute change vs.
elative change vs. transformed), which yield differing re-
ults, also complicates this issue. Standardized guidelines are
ecessary to guide research efforts and allow comparisons
etween studies in the field.
Measuring CAC progression also requires sequential CT
cans, with a cumulative radiation exposure. Prior reports
ave raised concern about the excess risk of cancer with such
n approach (29). However, such estimates will become
utdated as current gating technology has reduced the
adiation dose, with an achievable dose of 1 mSv/scan.
ssion occurs in 3 subgroups: 1) incident CAC; 2) calcified nonprogressors; and
AC score in this figure is for descriptive purposes only, and the numbers are not
ecome known as type 7 “calcified” lesions.
CAC Progression
Variability
Variability increases as baseline of absolute CAC increases (18)
Underestimates changes at higher levels of baseline CAC (19)
Variability still depends on the mean CVS (rho  0.66, p  0.0001) (18)
Removes the relation between variability and the mean CVS
(rho  0.09, p  0.15) (18)
Variance increases with increased mean CAC area (20)progre
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Coronary Artery Calcification Progression Review November 9, 2010:1613–22his compares favorably with other cardiac imaging modal-
ties used for risk stratification (8 mSv for a sestamibi
ardiac stress test).
The conscientious physician should also bear in mind that
iagnosing an asymptomatic subclinical disease can raise
nxiety and reduce future quality of life (30). Extracardiac
incidentalomas” are found in approximately 8% of cardiac
Ts, and the ramifications of such findings are often
nclear (31).
linical Determinants of CAC Progression
tudies relating clinical risk factors to CAC progression.
able 2 provides an overview of studies relating traditional
ardiac risk factors to CAC progression (31–39). This table
emonstrates that CAC progression has been related to all
raditional risk factors but that the relationship is not always
onsistent between studies. This finding might be a reflec-
ion of baseline cohort demographics or the measure of
AC progression used.
These traditional risk factors interact together when
nfluencing CAC progression. For example, Berry et al. (40)
ave shown that, even among 2,988 study participants with
ow 10-year risk of a cardiac event, those with a high
ifetime risk had significantly greater annual CAC progres-
ion (22% vs. 15% in men; 9% vs. 5% in women) compared
ith those with a low lifetime risk.
Some studies have also analyzed the effect of emerging
ovel cardiac risk factors on CAC progression. Such
ovel markers associated with CAC progression include:
-reactive protein (CRP) (41), Cystatin-C (42), poly-
orphisms of the renin-angiotensin genes (43), and low
diponectin levels (44).
maging parameters. In addition to being representative
f the pathophysiologic sum of prior cardiac risk factors,
aseline CAC score by cardiac CT is itself one of the
ost consistent predictors of future CAC progression
45,46). Gopal et al. (47) demonstrated that 62% of
ndividuals with zero CAC did not develop any calcifi-
ation, whereas only 2% had CAC progression 50 AUs
t follow-up of 5 years.
Other cardiac risk stratification imaging modalities have
een studied with regard to their relationship with CAC
rogression. Notably, increased carotid intima-media thick-
ess (48) by ultrasound (increasingly being used a surrogate
n cardiac clinical trials) and baseline thoracic aortic calcium
49) (less relevant to practice, because this is calculated by
ardiac CT at the same time that CAC is quantified) have
lso been correlated with CAC progression. The clinical
elevance of these associations remains to be defined; for
ow they serve to highlight the systemic nature of
therosclerosis.
linical Implications of CAC Progression
ngiographic measures of atherosclerosis progression have
een shown to predict clinical coronary events (50). How-ver, these findings cannot be directly extrapolated to CAC
rogression, because calcification only forms part of the
laque seen at angiography (Fig. 1). Given that this calcified
laque might be more clinically stable (9), one might arrive
t the conclusion that cardiac risk does not increase with
AC progression. However, this heuristic has been refuted
y available data (51).
Alternatively, increased local coronary calcification might
e associated with increased cardiac risk by its association
ith increased total plaque burden, including both noncal-
ified and mixed plaque subtypes (Fig. 1). Because less
ature plaques calcify after they rupture and heal, new
ighly calcified lesions might represent a propensity for
ctive atherosclerosis deposition and rupture throughout the
oronary tree. Research also suggests that mixed plaques,
hich contain early calcification near the plaque shoulders,
ncrease the propensity for plaque fracture (52).
This viewpoint has the support of emerging epidemio-
ogic data. Shemesh et al. (53) found a higher annual
rogression rate (180% increased from baseline score) in
atients who had coronary events compared with those who
id not (p  0.05). Another early retrospective study of 485
symptomatic patients treated with statins found a relative
isk of 17.2 for development of first myocardial infarction
ith CAC progression 15% (progressors) versus 15%
nonprogressors) over 3-year follow-up (54).
Raggi et al. (55) related the occurrence of myocardial
nfarction with CAC progression in 817 asymptomatic
ubjects referred for sequential EBCT imaging (average
nterval 2 years). The yearly mean absolute CVS change in
he 45 patients who had a myocardial infarction was 147,
ompared with 63 in those patients without events (p 
.001).
The St. Francis Heart Study prospectively evaluated the
rognostic accuracy of CAC progression in the prediction of
ardiac events in 4,613 adults between 50 and 70 years of
ge. Follow-up was over 4.3 years, and events occurred in
19 subjects (2.6%). In those without a cardiac event the
edian increase in CAC score was 4 AU. In contrast, those
ith a cardiac event had a median progression of CAC score
f 247 (51).
AC Progression and Therapeutic Interventions
or descriptive purposes and to facilitate accurate research
iscourse, we propose a schema for CAC progression and
he response of CAC to treatment that describes 3 sub-
roups (Fig. 1).
. Incident CAC, defined as detectable CAC at the
follow-up examination in a participant initially free of
CAC (41).
. Calcified nonprogressor, defined as an unchanged or
reduced CAC score in participants with detectable CAC
at baseline.
. Calcified progressor, defined as an increase in CAC score
in participants with detectable CAC at the initial exam-
Cardiac Risk Factors Associated With CAC ProgressionTable 2 Cardiac Risk Factors Associated With CAC Progression
Study/First Author
(Ref. #) Study Details
Blood
Pressure Cholesterol Age Diabetes FBG/HbA1c/MA/IR
Male
Sex Smoking Ethnicity
Family History
of CHD Obesity/BMI
Metabolic
Syndrome
Novel
Markers
MESA (41) n 5,756
48% men
Mean baseline age 62 yrs
Baseline total cholesterol: NR (14% on Rx)
Interval to follow-up CAC scan: 2.4 yrs
Method: natural logarithm  25 difference
in AU*
✓ ✓ ✓ ✓ ✓ FBG, ✓ MA ✓ ✓ ✓ White ✓ ✓  NR
ECAC (32) n  877
46% men
Mean baseline age 56 yrs
Baseline total cholesterol: NR
Interval to follow-up CAC scan: 7.3 yrs
Method: log change in CAC area*
✓ ✓ LDL ✓  NR ✓ ✓ NR  ✓ Waist:hip NR ✓ Genetic
Rancho Bernado
(33,34)
n  338
46% men
Mean baseline age 68 yrs
Baseline total cholesterol: 208 mg/dl
Interval to follow-up CAC scan: 4.5 yrs
Method: Hokanson*
✓ A A  ✓ FBG A A NR NR ✓ Abdominal
obesity
✓WHO NR
Lee et al. (35) n  869
62% men
Mean baseline age 66 yrs
Baseline total cholesterol: 205 mg/dl
Interval to follow-up CAC scan: 1 yr
Method: Hokanson*
✓ ✓  ✓ ✓ IR   ✓ White   NR  CRP
Costacou et al. (36) n  222 type 1 DM
47% men
Mean baseline age 38 yrs
Baseline total cholesterol: 190 mg/dl
Interval to follow-up CAC scan: 4 yrs
Method: Hokanson (AU)*
✓ ✓ ✓ A ✓ MA
 A1c
  NR NR ✓ NR NR
Anand et al. (37) n  398 type 2 DM
61% men
Mean baseline age 52 yrs
Baseline total cholesterol: 187 mg/dl
Interval to follow-up CAC scan: 2.5 yrs
Method: Hokanson (CVS)*
✓  ✓ ✓ DM
duration
✓ A1c 7 ✓  White NR ✓ Waist:hip NR ✓ IL-6
✓ OPG
 CRP
PREDICT (38) n  202 type 2 DM
68% men
Mean baseline age 62 yrs
Baseline total cholesterol: 187 mg/dl
Interval to follow-up CAC scan: 4 yrs
Method: CVS/AU annualized*
✓  ✓  DM
duration
✓ MA ✓  NR NR  BMI
✓ Waist:hip
  CRP
South Bay Heart
watch (39)
n  828
88% men
Mean baseline age 63 yrs
Baseline total cholesterol: NR
Interval to follow-up CAC scan: 7 yrs
Method: log transformed AU*
 HDL ✓ ✓ NR   ✓ White  Asian/
Pacific Islanders
NR ✓ NR NR
*Method used to quantify CAC progression.
A adjusted for in analysis; BMI body mass index; CHD coronary heart disease; CRP C-reactive protein; DM diabetes mellitus; ECAC Epidemiology of Coronary Artery Calcification; FBG fasting blood glucose; Hb hemoglobin; HDL high-density lipoprotein;
IL  interleukin; IR  insulin resistance; LDL  low-density lipoprotein; MA  micro-albuminuria; MESA  Multi-Ethnic Study of Atherosclerosis; NR  not reported; OPG  osteoprotegerin; PREDICT  patients with renal impairment and diabetes undergoing computed
tomography; WHO  World Health Organization definition for metabolic syndrome;   not associated with CAC progression; ✓  significantly associated with CAC progression; other abbreviations as in Table 1. 1617
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Coronary Artery Calcification Progression Review November 9, 2010:1613–22ination (41). This measure should account for interscan
variability and be clinically meaningful. For example,
Raggi et al. (54) suggested a 15%/year change in CVS;
Hokanson et al. (18) suggest a difference of 2.5 mm3
between the follow-up and baseline square root–trans-
formed CVS.
Published reports relating to CAC progression and ther-
peutic interventions are best categorized into statin studies
nd nonstatin studies (Table 3) (17,54,56–69).
tatin Studies
tatins reduce clinical cardiac end points across a spectrum
f patient populations (70). It seemed intuitive to early
esearchers that statins should reduce the progression of
AC. This was an attractive venture, because CAC quan-
ification could be used as a surrogate for events, potentially
educing the number of patients needed to evaluate the
ffectiveness of an intervention. However, the enthusiasm
romised by the results of early retrospective and prospec-
ive studies in this field (Table 3) did not bear fruit in
andomized controlled trials (RCTs).
SALTIRE (Scottish Aortic Stenosis and Lipid Lowering
rial, Impact on Regression) randomized 102 patients to
torvastatin or placebo and assessed CAC progression over
n average follow-up of 2 years. Despite a significant
eduction in low-density lipoprotein cholesterol (LDL-C)
nd CRP levels, there was a nonsignificant increase in
ercentage CAC progression (26%/year with atorvastatin
s. 18%/year with placebo) (60). An RCT by Terry et al.
61) with 80 subjects also found no difference in CAC
rogression in those treated with 80 mg of simvastatin
ersus placebo over 12 months (9% vs. 5%).
Another double-blind RCT by Schmermund et al. (62)
ailed to show reduced progression of CAC in 366 asymp-
omatic patients randomized to either 10 or 80 mg of
torvastatin over 12 months. This was despite a 20%
dditional reduction in LDL-C in the 80-mg atorvastatin
reatment group.
Although prior trials studied mostly men, 1 early study
ocumented CAC progression in post-menopausal women
71). The BELLES (Beyond Endorsed Lipid Lowering
ith EBCT Scanning) study was an RCT of hyperlipidemic
ost-menopausal women randomized to atorvastatin 80 mg
r pravastatin 40 mg. Most of the 4,739 screened were
xcluded for lipid levels below cutoff (63%) or baseline CVS
30 (42%). Of the 615 randomized, 475 received a
ollow-up EBCT at 1 year. Atorvastatin reduced LDL-C by
7%, whereas pravastatin reduced LDL-C by 25%. There
as no significant difference in CVS progression after 12
onths with an increase of 15% in the atorvastatin arm and
n increase of 14% for pravastatin (63). This study was
imited by lack of a placebo group.
Most CAC RCTs have compared LDL-C reduction
ith CAC progression. An inherent weakness in these trialss the use of surrogates for clinical events. There remains a meed for studies to correlate statin treatment with both
AC progression and cardiac events. The St. Francis Heart
tudy is the only such trial to date. This was a double-blind
CT of atorvastatin 20 mg daily, vitamin C 1 g daily, and
itamin E (alpha-tocopherol) 1,000 U daily versus matching
lacebos in 1,005 patients with coronary calcium scores at or
bove the 80th percentile for age and sex. Mean baseline
DL-C was 146 mg/dl, and CRP was 1.99 mg/l. Despite
ignificant reductions in LDL over a treatment course of 4.3
ears, there was no effect on CAC progression. There was a
on-statistically significant 30% reduction in cardiac events
n the overall cohort (p  0.08). However, there was a
ignificant 42% reduction in events in treated patients who
ad CAC 400 at baseline (8.7% vs. 15.0%, p  0.046)
64), suggesting that these patients might be suitable can-
idates for future primary prevention statin-CAC trials in a
ashion similar to a CRP 2 mg/l in JUPITER (Justifica-
ion for Use of Statins in Prevention: An Intervention Trial
valuating Rosuvastatin) (72).
So, why have statins been unsuccessful in reducing CAC
rogression? The AHA model of atherosclerosis, where
laque evolves from a noncalcified lesion to a calcified one,
s useful in conceptualizing the issue (Fig. 1). It is possi-
le to induce regression of the noncalcified portion of plaque
ith statin therapy (1). Whether this is possible with the
alcified portion of plaque is unknown. Animal models
uggest that a reduction in LDL-C does not decrease the
mount of plaque calcification at histology (73). Patholog-
cally, statins have been shown to promote micro-
alcification, which might lead to CAC score increases even
hen total atherosclerosis is reduced on statin therapy
73,74). This argument is bolstered by Burgstahler et al.
75), who used MDCT to assess CAC progression in men
reated with 20 mg/day of atorvastatin. They found no effect
n CAC progression but did note a significant reduction in
oncalcified plaque burden. Also, when statins reduce the
oft lipid core of a calcified plaque, the density of the plaque
nd its Agatston calcium score might increase, whereas its
olume might decrease.
This might explain why some of the early risk factor
tudies found an increased CAC progression rate with statin
herapy (although a major confounder is that those receiving
tatins have a history of dyslipidemia) (41). It seems
oubtful that the small increase in the incidence of diabetes
a risk factor associated with increased CAC progression)
ssociated with statin use is playing a role (76).
It is also possible that statins need more time to affect the
ownstream process of calcium deposition. Inadequate sta-
in intensity is an unlikely explanation for failure to reduce
AC progression, given the study by Hecht and Harman
59) of 182 patients followed over 1.2 years that failed to
how a difference in CAC progression in those treated to an
DL-C 80 mg/dl compared with those with more liberal
oals.
Finally, in the early observational studies, statin therapy
ight have introduced confounding if associated with better
CAC Progression: Therapeutic Studies to DateTable 3 CAC Progression: Therapeutic Studies to Date
First Author/Study
(Ref. #) Study Type Treatment Modality Patients (n)
% Baseline CAC  0;
Mean Baseline CAC
Follow-Up,
yrs
Baseline LDL and LDL
After Treatment
Change in CAC
Progression Rate (%) Event Data
Statin studies
Callister et al. (56) Retrospective Any statin vs. no statin 149 Unreported
750 CVS
1 Unreported baseline vs. LDL
120 mg/dl
45% reduced No
Raggi et al. (44) Retrospective Any statin vs. no statin 495 0%
327 CVS
3 Mean LDL 118 mg/dl vs.
122 mg/dl (p  NS)
35% reduced No
Budoff et al. (17) Prospective Any statin vs. no statin 131 27%
394 AU
2 Not reported 61% reduced No
Budoff et al. (57) Prospective diabetic
only
Any statin vs. no statin 163 6%
651 AU
1 Not reported 50% reduced No
Achenbach et al. (58) Prospective Cerivastatin vs. no statin 66 Unreported
155 CVS
2 Mean LDL from 164–107 mg/dl
with statin
64% reduced No
Hecht and Harman
(59)
Prospective Intensive statin Rx–LDL
80 mg/dl vs. liberal
statin Rx
182 Unreported
450 AU
1 LDL 201–65 mg/dl with
intensive Rx, 221–101 with
liberal Rx
No change No
SALTIRE (60) RCT Atorvastatin vs. placebo 102 24%
215 AU
2 Mean LDL from 135–67 mg/dl
with statin
44% increased (p  NS) No
Terry et al. (61) RCT Simvastatin vs. placebo 80 0%
650 AU
1 Mean LDL from 128–75 mg/dl
with statin
No change No
Schmermund et al.
(62)
RCT 80 mg atorvastatin vs.
10 mg atorvastatin
366 Uunreported
450 AU
1 LDL from 106–87 mg/dl with
80 mg, no change with
10 mg
No change No
BELLES (63) RCT 80 mg atorvastatin vs.
40 mg pravastatin
475 0% (CVS 30 excluded)
235 CVS
1 LDL 175–92 mg/dl with
atorvastatin, 173–129 mg/dl
with pravastatin
No change No
St. Francis Heart Study
(64)
RCT 20 mg atorvastatin vs.
placebo
1,005 Unreported
545 AU
4 LDL 146–98 mg/dl with statin No change Yes, no overall
difference
Nonstatin studies
Budoff et al. (65) Prospective Estrogen only HRT vs.
no HRT/combined HRT
177 Unreported 1 Not reported 63% reduced with estrogen
only HRT
No
Motro et al. (66) RCT, subgroup Nifedipine vs. amiloride/HCTZ 376 0%
110 AU
3 Not reported 50% reduced at 3 years No
Budoff et al. (67) RCT Aged garlic extract vs. placebo 65 Unreported
320 CVS
1 LDL 105–90 mg/dl with Rx,
no change with placebo
75% reduced No
Chertow et al. (68) RCT Sevelamer vs. calcium-based
phosphate binders
200 17%
1,418 AU
4 LDL 102–65 mg/dl with Rx,
no change with calcium
75% reduced Yes, mortality
reduced 5.3/100
patient-yrs
Qunibi et al. (69) RCT, nonblinded Intensive LDL (70 mg/dl)
with statins  sevelamer
vs. calcium PO4 binders
203 0% (CVS 30 excluded)
1,033 AU
1 LDL 108–62 mg/dl with
sevelamer, 112–69 mg/dl
with calcium
No change No
BELLES Beyond Endorsed Lipid Lowering with EBCT Scanning; HRT hormone replacement therapy; LDL low density lipoprotein; RCT randomized control trial; Rx treatment; SALTIRE Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression; other
abbreviations as in Table 1.
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rolled for this possibility and might have ameliorated the
ffect seen. More studies evaluating the effect of other
stablished cardiac preventive medications and their rela-
ionship to CAC progression and cardiac outcomes are
eeded.
onstatin Studies
here is a paucity of data on whether treating other cardiac
isk factors can reduce CAC progression. In a subgroup of
01 patients from INSIGHT (International Nifedipine
tudy: Intervention as Goal for Hypertension Therapy),
ifedipine demonstrated significant inhibition of coronary
alcium progression over 3 years compared with amiloride/
ydrochlorothiazide (40% vs. 78%, p  0.02) (66). Similar
ncouraging results have been found with unopposed estro-
en hormone replacement (65) and aged garlic extracts and
upplements (67).
Cardiovascular mortality rates in dialysis patients are, on
verage, 30-fold higher than the general population (77).
ursztyn et al. (78) also found that, among high-risk
ypertensive patients, even mild renal dysfunction is asso-
iated with faster CAC progression. Chertow et al. (68)
ound that, compared with calcium-based phosphate bind-
rs, sevelamer is associated with less progressive coronary
alcification in hemodialysis patients at 1 year. Sevelamer is
nown to reduce LDL-C levels, independent of other
edications. In a trial with concomitant intensive lowering
f LDL-C levels for 1 year, hemodialysis patients treated
ith either calcium acetate plus atorvastatin versus sevelamer
lus atorvastatin experienced similar progression of CAC (69).
ecommendations and Future Directions
here are currently no published guidelines for physicians
r researchers who wish to quantify progression of subclin-
cal atherosclerosis by CAC. The limited data to date
uggest that CAC progression may be a more accurate
redictor of future cardiac risk than baseline CAC alone
51). However, the clinical utility of this is unknown. No
rospective comparison has been undertaken to evaluate
herapy decisions based on serial CAC scanning versus
aseline CAC scanning alone. Such a study would need to
ustify the repeat exposure to radiation needed to quantify
rogression.
Therefore, serial CAC quantification cannot be routinely
ecommended on the basis of current evidence. However,
e believe it has considerable potential as a noninvasive
easure of the progression of atherosclerosis and might
ave ongoing applicability to the study of interventions
argeted at reducing this progression. Further research is
eeded to explore whether this potential can be fulfilled.
We recommend the transformed square root method of
okanson for quantifying progression, because it minimizes
oth variability and the effect of the baseline score on
rogression. We recommend that CAC scores be reportedy CVS, with or without Agatston scores, to facilitate
niversal comparisons of CAC progression by the Hokan-
on method across future trials.
Future directions in research include: prospectively study-
ng the difference in predictive power between baseline
AC alone and CAC progression, further evaluating the
ffect of both traditional and novel cardiac risk factors on
AC progression to better understand their relationship to
therosclerosis, study of other established (nonstatin) car-
iac medications to explore their relationship to CAC
rogression and cardiac outcomes, and studying the optimal
ime interval for measuring progression. With regard to the
atter, Min et al. (46) have prospectively found that incident
AC occurs at low frequency before 4 years in those with
aseline low to intermediate risk and 0-baseline CAC. The
ptimal time for retesting those with positive baseline CAC
CAC progressors) remains unknown, although this interval
ill likely be related to the severity of baseline CAC (46).
onclusions
rogression of CAC is associated with multiple cardiac risk
actors. In most observational studies, increased rates of
AC progression have been shown to increase the risk for
uture cardiac events. Despite this, there has been a lack of
uccess in retarding CAC progression with statin therapy,
nderscoring the point that CAC progression might not
quate exactly with pathologic atherosclerosis progression.
ittle is known of the clinical implications of decreasing
AC progression with therapy, and it is unclear whether
ecreased CAC progression can be achieved with currently
vailable medications. The best measure of CAC progres-
ion seems to be the Hokanson method, but no prospective
omparisons have been performed between the various
easurement options. More prospective data are needed to
urther elucidate whether quantifying CAC progression can
e recommended for cardiac risk stratification in clinical
ractice or can be used as a surrogate for clinical end points
n future therapeutic trials.
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